Teun van der Bom1, Barbara J M Mulder1, Folkert J Meijboom2, Arie P J van Dijk3, Petronella G Pieper4, Hubert W Vliegen5, Thelma C Konings6, Aeilko H Zwinderman7, Berto J Bouma8. 1. Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands The Netherlands Heart Institute, Utrecht, The Netherlands. 2. Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands. 3. Department of Cardiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 4. Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. 6. Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands. 7. Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands. 8. Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Survival data that are applicable to the current population of adults with congenital heart disease (CHD) are not available. OBJECTIVES: Using an alternative survival analysis with age as the primary time scale, we assessed the contemporary survival of adult patients with CHD. METHODS: Survival was assessed using prospective data of the national registry of adult patients with CHD of the Netherlands. Survival was stratified by severity and lesion, and compared with a standardised general population. RESULTS: Mean age at inclusion was 37 years, and 49% of the study population was male. During a cumulative prospective follow-up of 90, 270 patient-years in 14, 327 patients, 535 deaths occurred. Median survival was 53.4 (95% CI 49.9 to 60.7), 75.4 (95% CI 72.9 to 79.1) and 84.1 (95% CI 81.9 to 87.0) years for patients with severe, moderate and mild lesions, respectively. Survival of most patients with mild lesions did not differ from the general population, while, as expected, survival of patients with severe and moderate lesions was substantially lower (<0.001). CONCLUSIONS: The present study gives insight in the contemporary survival of adults with CHD. This may aid patient counselling, timing of interventions and future research. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
BACKGROUND: Survival data that are applicable to the current population of adults with congenital heart disease (CHD) are not available. OBJECTIVES: Using an alternative survival analysis with age as the primary time scale, we assessed the contemporary survival of adult patients with CHD. METHODS: Survival was assessed using prospective data of the national registry of adult patients with CHD of the Netherlands. Survival was stratified by severity and lesion, and compared with a standardised general population. RESULTS: Mean age at inclusion was 37 years, and 49% of the study population was male. During a cumulative prospective follow-up of 90, 270 patient-years in 14, 327 patients, 535 deaths occurred. Median survival was 53.4 (95% CI 49.9 to 60.7), 75.4 (95% CI 72.9 to 79.1) and 84.1 (95% CI 81.9 to 87.0) years for patients with severe, moderate and mild lesions, respectively. Survival of most patients with mild lesions did not differ from the general population, while, as expected, survival of patients with severe and moderate lesions was substantially lower (<0.001). CONCLUSIONS: The present study gives insight in the contemporary survival of adults with CHD. This may aid patient counselling, timing of interventions and future research. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: Odilia I Woudstra; Joey M Kuijpers; Folkert J Meijboom; Marco C Post; Monique R M Jongbloed; Anthonie L Duijnhouwer; Arie P J van Dijk; Joost P van Melle; Thelma C Konings; Aeilko H Zwinderman; Barbara J M Mulder; Berto J Bouma Journal: Eur Heart J Cardiovasc Pharmacother Date: 2019-10-01
Authors: Odilia I Woudstra; Tjitske E Zandstra; Rosanne F Vogel; Arie P J van Dijk; Hubert W Vliegen; Philippine Kiès; Monique R M Jongbloed; Anastasia D Egorova; Pieter A F M Doevendans; Thelma C Konings; Barbara J M Mulder; Michael W T Tanck; Folkert J Meijboom; Berto J Bouma Journal: J Am Heart Assoc Date: 2021-02-22 Impact factor: 5.501
Authors: Alexander Isaak; Julian A Luetkens; Anton Faron; Christoph Endler; Narine Mesropyan; Christoph Katemann; Shuo Zhang; Patrick Kupczyk; Daniel Kuetting; Ulrike Attenberger; Darius Dabir Journal: J Cardiovasc Magn Reson Date: 2021-07-19 Impact factor: 5.364
Authors: Ari M Cedars; Jong Mi Ko; Anitha S John; Jeffrey Vittengl; Ada C Stefanescu-Schmidt; Robin B Jarrett; Shelby Kutty; John A Spertus Journal: J Am Heart Assoc Date: 2020-05-16 Impact factor: 5.501